• Fund Type: Open-End Fund
  • Objective: Growth Small Cap
  • Asset Class: Equity
  • Geographic Focus: U.S.

Dreyfus/The Boston Company Small Cap Growth Fund

+ Add to Watchlist

SSYGX:US

36.42 USD 0.08 0.22%

As of 09:29:30 ET on 12/19/2014.

Snapshot for Dreyfus/The Boston Company Small Cap Growth Fund (SSYGX)

Year To Date: +1.77% 3-Month: +6.19% 3-Year: - 52-Week Range: 32.72 - 39.68
1-Month: +4.48% 1-Year: +5.58% 5-Year: - Beta vs RUO: -

Mutual Fund Chart for SSYGX

No chart data available.
  • SSYGX:US 36.42
  • 1M
  • 1Y
Interactive SSYGX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for SSYGX

Dreyfus/The Boston Company Small Cap Growth Fund is an open-end fund incorporated in the USA. The Fund's objective seeks long-term growth of capital. The Fund invests all of its investible assets in a Standish master portfolio which invests, under normal circumstances, at least 80% of net assets in equity securities of small cap U.S. companies.

Inception Date: 07-01-2013 Telephone: 1-800-346-8893 Domestic
Managers: TODD W WAKEFIELD / ROBERT ZEUTHEN
Web Site: www.dreyfus.com

Fundamentals for SSYGX

NAV (on 2014-12-19) 36.42
Assets (M) (on 2014-12-19) 31.47
Fund Leveraged N
Minimum Investment 1,000,000.00
Minimum Subsequent Investment 0.00

Dividends for SSYGX

No dividends reported

Fees & Expenses for SSYGX

Front Load 0.00
Back Load 0.00
Current Mgmt Fee 0.80
Redemption Fee -
12b1 Fee -
Expense Ratio 0.95

Top Fund Holdings for SSYGX

Filing Date: 10/31/2014
Name Position Value % of Total
iShares Russell 2000 Growth ET 9,700 1,335,011 2.704%
Anacor Pharmaceuticals Inc 33,770 993,176 2.012%
BioDelivery Sciences Internati 54,540 948,996 1.922%
Watsco Inc 9,120 926,774 1.877%
WuXi PharmaTech Cayman Inc 24,510 924,027 1.872%
Aruba Networks Inc 38,338 827,334 1.676%
Advisory Board Co/The 15,284 820,292 1.662%
LogMeIn Inc 16,250 780,813 1.582%
Inphi Corp 50,357 779,526 1.579%
Nektar Therapeutics 56,480 778,859 1.578%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil